These emerging therapies , Retatrutide, represent a significant advancement in managing metabolic dysfunction and possibly other ailments . They are grouped as GLP-1 pathway agonists , meaning they function to mimic the body's GLP-1 hormone , boosting glucose release and reducing food intake. Although Semaglutide each one operates somewhat similarl